Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
240 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-04-25
Study Completion Date
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Graves' disease (GD) is an autoimmune thyroid disorder caused by stimulating auto-antibodies to the thyrotrophin (TSH) receptor on thyroid follicular cells. It is the most common cause of hyperthyroidism and approximately 3% of women and 0.5% of men develop GD in their lifetime.
RAI has been shown to be a cost-effective and safe therapy in patients with GD but with some disadvantages. In addition, despite its proven efficacy and safety, many patients do not wish to undergo RAI because of radiation fear and prefer to either continue ATDs or have surgery.
High-intensity focused ultrasound (HIFU) is a non-invasive procedure that involves the application of a high-energy focused beam for thermal tissue ablation within a targeted zone. Similar to the principle of RAI (i.e. using ionizing radiation to ablate thyroid parenchyma and cause GD remission), we postulated that the heat energy generated from HIFU could also be used to ablate the thyroid parenchyma and cause GD remission. The idea of using heat energy to ablate thyroid parenchyma minimally invasively was recently reported using radiofrequency ablation but to our knowledge, we are one of the first (if not the first) group to propose using HIFU energy to ablate thyroid parenchyma as a definitive treatment for relapsed GD.
Having obtained ethical approval, a pilot study was conducted to examine the efficacy and safety of HIFU as a treatment for relapsed GD. In the pilot study, all patients underwent a safe and successful HIFU ablation for relapsed GD. Based on the results of the pilot study, we hypothesize that a single HIFU treatment to the thyroid gland may be as effective as our standard outpatient fixed-dose of RAI (370MBq) in causing remission of GD at 6-month. If our hypothesis turns out to be true, HIFU could become a treatment option for patients who are indicated for RAI but do not wish to have it because of one reason or another. HIFU appears to induce a faster disease remission and lessen the need of deferring pregnancy and radiation precautions because of the absence of radioactivity.
RAI has been shown to be a cost-effective and safe therapy in patients with GD but with some disadvantages. In addition, despite its proven efficacy and safety, many patients do not wish to undergo RAI because of radiation fear and prefer to either continue ATDs or have surgery.
High-intensity focused ultrasound (HIFU) is a non-invasive procedure that involves the application of a high-energy focused beam for thermal tissue ablation within a targeted zone. Similar to the principle of RAI (i.e. using ionizing radiation to ablate thyroid parenchyma and cause GD remission), we postulated that the heat energy generated from HIFU could also be used to ablate the thyroid parenchyma and cause GD remission. The idea of using heat energy to ablate thyroid parenchyma minimally invasively was recently reported using radiofrequency ablation but to our knowledge, we are one of the first (if not the first) group to propose using HIFU energy to ablate thyroid parenchyma as a definitive treatment for relapsed GD.
Having obtained ethical approval, a pilot study was conducted to examine the efficacy and safety of HIFU as a treatment for relapsed GD. In the pilot study, all patients underwent a safe and successful HIFU ablation for relapsed GD. Based on the results of the pilot study, we hypothesize that a single HIFU treatment to the thyroid gland may be as effective as our standard outpatient fixed-dose of RAI (370MBq) in causing remission of GD at 6-month. If our hypothesis turns out to be true, HIFU could become a treatment option for patients who are indicated for RAI but do not wish to have it because of one reason or another. HIFU appears to induce a faster disease remission and lessen the need of deferring pregnancy and radiation precautions because of the absence of radioactivity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease
NCT02685514
Rrelapsed Graves' Disease
COMPLETED
NA
HIFU Ablation vs Fixed-dose RAI-131 Therapy in Moderate-sized Non-toxic MNG
NCT04009863
Non Toxic Multinodular Goiter
High Intensity Focused Ultrasound
RAI
COMPLETED
NA
A Prospective Evaluation of Microwave Ablation (MWA) in the Treatment of Relapsed Graves' Disease
NCT06506149
Graves Disease
Minimally Invasive Treatment
Ablation Treatment
RECRUITING
NA
Low-dose Radioiodine Ablation in Graves' Disease
NCT03110835
Thyroid Diseases
COMPLETED
Comparative Study of Different I-131 Doses in Graves' Disease
NCT02114619
Graves' Disease
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Graves' disease (GD) is an autoimmune thyroid disorder caused by stimulating auto-antibodies to the thyrotrophin (thyroid stimulating hormone \[TSH\]) receptor on thyroid follicular cells. It is the most common cause of hyperthyroidism and approximately 3% of women and 0.5% of men develop GD in their lifetime1. In our locality, like Europe and Japan, antithyroid drugs (ATDs) such as carbimazole or propylthiouracil have been preferred over radioactive iodine (RAI) and surgery as the initial treatment of GD2-4. This is because ATDs are relatively easy to administer, could induce disease remission (30-70%) and avoid life-long thyroid hormone replacement, operative risks and radioactivity2-4. However, because of possible side-effects, they are only recommended for a period of 12 to 18 months. Taking ATDs for a longer period does not seem to increase the chance of remission5. Therefore, currently, once the disease has relapsed after a 18-month of ATD treatment, more definitive treatment modalities like RAI or surgery are indicated. Regarding to which is more preferable, surgery is usually advised in patients with large compressive goiter (\>80g), suspected or documented thyroid malignancy, planning to become pregnant within 6 months and moderate to severe Graves' ophthalmopathy (GO)2-4. As a result, most patients without these conditions are considered for RAI2-4.
RAI has been shown to be a cost-effective and safe therapy in patients with GD4,6,7. In North America, clinical endocrinologists favor RAI as the initial treatment for GD2-4. However, since RAI is usually prescribed on an outpatient basis, it is necessary to consider nearby individuals' exposure doses and formulate radiation precautions carefully8. Other disadvantages include its slow induction of euthyroidism, potential worsening of GO and deferral of pregnancy2-4. Although various dosing techniques have been described to ensure an adequate radiation delivery to the thyroid gland, the simplest and most effective method has been to administer a fixed dose of RAI2. However, due to local regulations and our densely-populated areas, administering higher RAI doses (\>400MBq) is not permitted on an outpatient basis9. As a result, the usual RAI dose usually ranges between 185 to 370MBq (i.e. up to 10mci)10. In addition, despite its proven efficacy and safety, many patients do not wish to undergo RAI because of radiation fear and prefer to either continue ATDs or have surgery11.
High-intensity focused ultrasound (HIFU) is a non-invasive procedure that involves the application of a high-energy focused beam for thermal tissue ablation within a targeted zone. It has been applied in a variety of medical conditions including uterine fibroids and prostate, breast, pancreatic, and liver tumors12. Unlike other ablation devices (like radiofrequency or laser ablation), HIFU does not require needle puncture and is considered safer and less operator-dependent13. Single HIFU treatment has been shown to reduce size of benign thyroid nodules13,14. Histologic examination confirmed that HIFU induced complete tissue necrosis within a targeted area13. Similar to the principle of RAI (i.e. using ionizing radiation to ablate thyroid parenchyma and cause GD remission), we postulated that the heat energy generated from HIFU could also be used to ablate the thyroid parenchyma and cause GD remission. The idea of using heat energy to ablate thyroid parenchyma minimally invasively was recently reported using radiofrequency ablation15 but to our knowledge, we are one of the first (if not the first) group to propose using HIFU energy to ablate thyroid parenchyma as a definitive treatment for relapsed GD.
Having obtained ethical approval, a pilot study was conducted to examine the efficacy and safety of HIFU as a treatment for relapsed GD. Over a 2-month period, 20 patients underwent a single HIFU treatment for relapsed GD. The treatment involved ablating the entire right, left and central (isthmic) lobes with HIFU pulses. To avoid inadvertent injury to heat-sensitive structures like the recurrent laryngeal nerve, parathyroid glands, trachea and esophagus, we deliberately left 2-3ml of thyroid parenchyma non-ablated close to the trachea-esophageal groove on each side. The reason for not leaving a larger amount of non-ablated parenchyma is because from the experience in subtotal thyroidectomy, leaving \> 6ml of normal parenchyma may diminish the long-term remission rate16.
In the pilot study, all patients underwent a safe and successful HIFU ablation for relapsed GD. By ultrasound (USG) volumetry, the mean pre-ablation total thyroid volume was 18.5 ± 6.4ml. The average treatment time was 72.7 ± 31.0 mins and the total energy delivered to each patient was 21.4 ± 5.9 KJ. No patients suffered any major complications afterwards except for 2 patients (10.0%) who had minor neck redness in the first week. By 4-week, all patients were either biochemically euthyroid (n=15) (without ATDs) or biochemically hypothyroid (requiring thyroxine replacement) (n=5). At 6-month, 15 (75.0%) patients remained biochemically euthyroid or hypothyroid without ATDs (i.e. remission) while 5 patients (25.0%) had biochemical hyperthyroidism. However, of these, only 3 required ATDs and 2 were kept observed.
Based on the results of the pilot study, we hypothesize that a single HIFU treatment to the thyroid gland may be as effective as our standard outpatient fixed-dose of RAI (370MBq) in causing remission of GD at 6-month. If our hypothesis turns out to be true, HIFU could become a treatment option for patients who are indicated for RAI but do not wish to have it because of one reason or another. Apart from the benefit of being an outpatient treatment, HIFU appears to induce a faster disease remission and lessen the need of deferring pregnancy and radiation precautions because of the absence of radioactivity.
RAI has been shown to be a cost-effective and safe therapy in patients with GD4,6,7. In North America, clinical endocrinologists favor RAI as the initial treatment for GD2-4. However, since RAI is usually prescribed on an outpatient basis, it is necessary to consider nearby individuals' exposure doses and formulate radiation precautions carefully8. Other disadvantages include its slow induction of euthyroidism, potential worsening of GO and deferral of pregnancy2-4. Although various dosing techniques have been described to ensure an adequate radiation delivery to the thyroid gland, the simplest and most effective method has been to administer a fixed dose of RAI2. However, due to local regulations and our densely-populated areas, administering higher RAI doses (\>400MBq) is not permitted on an outpatient basis9. As a result, the usual RAI dose usually ranges between 185 to 370MBq (i.e. up to 10mci)10. In addition, despite its proven efficacy and safety, many patients do not wish to undergo RAI because of radiation fear and prefer to either continue ATDs or have surgery11.
High-intensity focused ultrasound (HIFU) is a non-invasive procedure that involves the application of a high-energy focused beam for thermal tissue ablation within a targeted zone. It has been applied in a variety of medical conditions including uterine fibroids and prostate, breast, pancreatic, and liver tumors12. Unlike other ablation devices (like radiofrequency or laser ablation), HIFU does not require needle puncture and is considered safer and less operator-dependent13. Single HIFU treatment has been shown to reduce size of benign thyroid nodules13,14. Histologic examination confirmed that HIFU induced complete tissue necrosis within a targeted area13. Similar to the principle of RAI (i.e. using ionizing radiation to ablate thyroid parenchyma and cause GD remission), we postulated that the heat energy generated from HIFU could also be used to ablate the thyroid parenchyma and cause GD remission. The idea of using heat energy to ablate thyroid parenchyma minimally invasively was recently reported using radiofrequency ablation15 but to our knowledge, we are one of the first (if not the first) group to propose using HIFU energy to ablate thyroid parenchyma as a definitive treatment for relapsed GD.
Having obtained ethical approval, a pilot study was conducted to examine the efficacy and safety of HIFU as a treatment for relapsed GD. Over a 2-month period, 20 patients underwent a single HIFU treatment for relapsed GD. The treatment involved ablating the entire right, left and central (isthmic) lobes with HIFU pulses. To avoid inadvertent injury to heat-sensitive structures like the recurrent laryngeal nerve, parathyroid glands, trachea and esophagus, we deliberately left 2-3ml of thyroid parenchyma non-ablated close to the trachea-esophageal groove on each side. The reason for not leaving a larger amount of non-ablated parenchyma is because from the experience in subtotal thyroidectomy, leaving \> 6ml of normal parenchyma may diminish the long-term remission rate16.
In the pilot study, all patients underwent a safe and successful HIFU ablation for relapsed GD. By ultrasound (USG) volumetry, the mean pre-ablation total thyroid volume was 18.5 ± 6.4ml. The average treatment time was 72.7 ± 31.0 mins and the total energy delivered to each patient was 21.4 ± 5.9 KJ. No patients suffered any major complications afterwards except for 2 patients (10.0%) who had minor neck redness in the first week. By 4-week, all patients were either biochemically euthyroid (n=15) (without ATDs) or biochemically hypothyroid (requiring thyroxine replacement) (n=5). At 6-month, 15 (75.0%) patients remained biochemically euthyroid or hypothyroid without ATDs (i.e. remission) while 5 patients (25.0%) had biochemical hyperthyroidism. However, of these, only 3 required ATDs and 2 were kept observed.
Based on the results of the pilot study, we hypothesize that a single HIFU treatment to the thyroid gland may be as effective as our standard outpatient fixed-dose of RAI (370MBq) in causing remission of GD at 6-month. If our hypothesis turns out to be true, HIFU could become a treatment option for patients who are indicated for RAI but do not wish to have it because of one reason or another. Apart from the benefit of being an outpatient treatment, HIFU appears to induce a faster disease remission and lessen the need of deferring pregnancy and radiation precautions because of the absence of radioactivity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Graves Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High Intensity Focused Ultrasound
Try to use the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the relapsed Graves' disease
Group Type
EXPERIMENTAL
Echopulse
Intervention Type
DEVICE
Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
Fixed-dose radioiodine-131
Using the traditional treatment, fixed-dose radioiodine-131, to treat the relapsed Graves' disease
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Echopulse
Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
Intervention Type
DEVICE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
High Intensity Focused Ultrasound (HIFU)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. A diagnosis of GD based on standard clinical criteria (elevated thyroid hormone levels, suppressed TSH, positive TSHR auto-antibody, diffuse goiter ± high RAI uptake).
2. Aged between 18 and 70 years old at the time of informed consent
3. Have had at least one GD relapse. A relapse is defined as recurrent or persistent hyperthyroidism despite completing a continued course of ATDs for 18 months or more.
4. Indicated for RAI treatment
5. Valid consent is obtained
2. Aged between 18 and 70 years old at the time of informed consent
3. Have had at least one GD relapse. A relapse is defined as recurrent or persistent hyperthyroidism despite completing a continued course of ATDs for 18 months or more.
4. Indicated for RAI treatment
5. Valid consent is obtained
Exclusion Criteria
1. Prefer or have clear indications for surgery (such as those with large compressive goiter, suspected or documented thyroid malignancy, wishing to become pregnant within 6 months or with moderate to severe GO).
2. Have pre-existing vocal cord palsy
3. Are unable to move or extend their neck
4. Have either right, left or central (isthmic) lobe measuring \>30ml in volume on pre-treatment USG volumetry (see later)
5. Have concomitant thyroid nodules which are either indeterminate, suspicious of malignancy or proven malignant on fine needle aspiration cytology (FNAC).
6. Have active or severe Graves ophthalmopathy (GO)
7. Are pregnant, lactating or planning for pregnancy within 6 months
8. Have any medical conditions that would make them too ill to undergo intravenous sedation or treatment
9. Any condition that is unstable or can jeopardize the safety of the patients and their compliance to the study
2. Have pre-existing vocal cord palsy
3. Are unable to move or extend their neck
4. Have either right, left or central (isthmic) lobe measuring \>30ml in volume on pre-treatment USG volumetry (see later)
5. Have concomitant thyroid nodules which are either indeterminate, suspicious of malignancy or proven malignant on fine needle aspiration cytology (FNAC).
6. Have active or severe Graves ophthalmopathy (GO)
7. Are pregnant, lactating or planning for pregnancy within 6 months
8. Have any medical conditions that would make them too ill to undergo intravenous sedation or treatment
9. Any condition that is unstable or can jeopardize the safety of the patients and their compliance to the study
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Hong Kong
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Lang Hung Hin, Brian
Clinical Associate Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hung Hin, Brian Lang, MBBS(Hons)
Role: PRINCIPAL_INVESTIGATOR
The University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Queen Mary Hospital
Hong Kong, , Hong Kong
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Hong Kong
References
Explore related publications, articles, or registry entries linked to this study.
Nystrom HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol (Oxf). 2013 May;78(5):768-76. doi: 10.1111/cen.12060.
Reference Type
BACKGROUND
Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011 Jun;21(6):593-646. doi: 10.1089/thy.2010.0417. Epub 2011 Apr 21.
Reference Type
BACKGROUND
Burch HB, Cooper DS. Management of Graves Disease: A Review. JAMA. 2015 Dec 15;314(23):2544-54. doi: 10.1001/jama.2015.16535.
Reference Type
BACKGROUND
Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012 Mar 24;379(9821):1155-66. doi: 10.1016/S0140-6736(11)60782-4. Epub 2012 Mar 5.
Reference Type
BACKGROUND
Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005 Oct;153(4):489-98. doi: 10.1530/eje.1.01993.
Reference Type
BACKGROUND
Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013 Sep;98(9):3671-7. doi: 10.1210/jc.2013-1954. Epub 2013 Jul 3.
Reference Type
BACKGROUND
Patel NN, Abraham P, Buscombe J, Vanderpump MP. The cost effectiveness of treatment modalities for thyrotoxicosis in a U.K. center. Thyroid. 2006 Jun;16(6):593-8. doi: 10.1089/thy.2006.16.593.
Reference Type
BACKGROUND
Liu B, Tian R, Peng W, He Y, Huang R, Kuang A. Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements. J Clin Endocrinol Metab. 2015 Aug;100(8):2934-41. doi: 10.1210/jc.2015-1682. Epub 2015 Jun 5.
Reference Type
BACKGROUND
Yau JS, Chu KS, Li JK, Chan KW, Lau IT, Yum SW, Chan CW, Mo LK, Kwan WK. Usage of a fixed dose of radioactive iodine for the treatment of hyperthyroidism: one-year outcome in a regional hospital in Hong Kong. Hong Kong Med J. 2009 Aug;15(4):267-73.
Reference Type
BACKGROUND
Yip J, Lang BH, Lo CY. Changing trend in surgical indication and management for Graves' disease. Am J Surg. 2012 Feb;203(2):162-7. doi: 10.1016/j.amjsurg.2011.01.029. Epub 2011 Jun 17.
Reference Type
BACKGROUND
Zhou YF. High intensity focused ultrasound in clinical tumor ablation. World J Clin Oncol. 2011 Jan 10;2(1):8-27. doi: 10.5306/wjco.v2.i1.8.
Reference Type
BACKGROUND
Esnault O, Franc B, Chapelon JY. Localized ablation of thyroid tissue by high-intensity focused ultrasound: improvement of noninvasive tissue necrosis methods. Thyroid. 2009 Oct;19(10):1085-91. doi: 10.1089/thy.2009.0121.
Reference Type
BACKGROUND
Kovatcheva RD, Vlahov JD, Stoinov JI, Zaletel K. Benign Solid Thyroid Nodules: US-guided High-Intensity Focused Ultrasound Ablation-Initial Clinical Outcomes. Radiology. 2015 Aug;276(2):597-605. doi: 10.1148/radiol.15141492. Epub 2015 Mar 13.
Reference Type
BACKGROUND
Long B, Li L, Yao L, Chen S, Yi H, Ye X, Xu D, Wu P. Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma. J Cancer Res Ther. 2015 Nov;11 Suppl:C244-7. doi: 10.4103/0973-1482.170530.
Reference Type
BACKGROUND
Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves' disease: A meta-analysis. J Surg Res. 2000 May 15;90(2):161-5. doi: 10.1006/jsre.2000.5875.
Reference Type
BACKGROUND
Von Hofe SE, Dorfman SG, Carretta RF, Young RL. The increasing incidence of hypothyroidism within one year after radioiodine therapy for toxic diffuse goiter. J Nucl Med. 1978 Feb;19(2):180-4.
Reference Type
BACKGROUND
Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab. 2003 Mar;88(3):978-83. doi: 10.1210/jc.2002-020805.
Reference Type
BACKGROUND
Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM; European Group on Graves' Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008 Mar;158(3):273-85. doi: 10.1530/EJE-07-0666. No abstract available.
Reference Type
BACKGROUND
Wong KP, Lang BH, Ng SH, Cheung CY, Chan CT, Lo CY. A prospective, assessor-blind evaluation of surgeon-performed transcutaneous laryngeal ultrasonography in vocal cord examination before and after thyroidectomy. Surgery. 2013 Dec;154(6):1158-64; discussion 1164-5. doi: 10.1016/j.surg.2013.04.063. Epub 2013 Aug 19.
Reference Type
BACKGROUND
Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355-71. doi: 10.2165/00019053-200624040-00006.
Reference Type
BACKGROUND
Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf). 2004 Nov;61(5):641-8. doi: 10.1111/j.1365-2265.2004.02152.x.
Reference Type
BACKGROUND
Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health. 2012 Sep-Oct;15(6):812-20. doi: 10.1016/j.jval.2012.06.014.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.rbhk.org.hk/eng/ordin-cap303.html
Hong Kong Radiation Ordinance Chapter 303
http://www.gld.gov.hk/egazette/english/gazette/toc.php
Revisions to List of charges: G.N. 1488 to Gazette No. 12/2013
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UW 16-565
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Clinical Study of Ultrasound-guided Radiofrequency Ablation in the Treatment of Refractory Hyperthyroidism
NCT06305871
ACTIVE_NOT_RECRUITING
NA
Assessment of Thyroid Doppler Ultrasound in Followup of Pediatric Graves' Disease
NCT06357494
NOT_YET_RECRUITING
High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules
NCT02169687
TERMINATED
EARLY_PHASE1
Outcome of RAI131 Therapy in Patients With Differentiated Thyroid Cancer (Low and Intermediate Risk)
NCT07056218
NOT_YET_RECRUITING
TSI and Its Relationship With Graves' Disease Relapse
NCT05713097
COMPLETED
HIFU in Patients With Non-malignant Thyroid Nodules
NCT02258347
COMPLETED
NA
A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
NCT07040306
RECRUITING
Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism
NCT01039818
COMPLETED
PHASE3
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease
NCT02316691
TERMINATED
rhTSH-Thyroid Ablation With 1850 MBq of 131I
NCT00454077
COMPLETED
Three-Year Follow-up of Radioiodine Therapy for Goitre
NCT00509483
COMPLETED
NA
Factors Affecting Timing of Hypothyroidism Following Radioactive Iodine Therapy Patients With Graves Disease
NCT05643365
UNKNOWN
Clinical Value of Microvascular Ultrasonography in Real-time Differential Diagnosis of Thyrotoxic Patients
NCT04879173
UNKNOWN
The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions
NCT01204359
UNKNOWN
PHASE3
rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter
NCT00275171
COMPLETED
PHASE2
Optimization With a Gamma Camera of the Individualized Patient Dosimetry in Radioiodine Therapy of Thyroid Diseases
NCT06371339
COMPLETED
NA
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
NCT07261345
RECRUITING
EARLY_PHASE1
Radioactive Iodide Therapy for Pediatric Graves' Disease
NCT01269749
COMPLETED
PHASE2
Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease
NCT01182584
UNKNOWN
Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
NCT00181168
COMPLETED
PHASE2
In Vivo CAR-T for Refractory Graves' Disease
NCT07333677
RECRUITING
EARLY_PHASE1
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
NCT07129642
RECRUITING
EARLY_PHASE1
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
NCT07152366
RECRUITING
PHASE4
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
NCT07152340
RECRUITING
PHASE4
Recurrence in Patients With Differentiated Thyroid Cancer
NCT06154863
NOT_YET_RECRUITING